EnteroBiotix, a leading clinical stage microbiome therapeutics company headquartered in Aberdeen, Scotland, has closed an oversubscribed seed extension investment and is set for international... read more
EnteroBiotix, a leading clinical stage microbiome therapeutics company headquartered in Aberdeen, Scotland, has closed an oversubscribed seed extension investment and is set for international... read more
Fort Worth, TX May 28, 2019 — SOURCE EXPLORER, a life sciences supplier search and matching service, announced today that it has... read more
Microbiome Report for Week Ending 5/18/19
4D Pharma's Chron's Disease Treatment Meets Safety Objective
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on... read more
Stoke Therapeutics filed for its IPO that could be worth up to $86 million. The Bedford, MA-based company is developing therapies to treat severe genetic diseases by, “precisely protein... read more
Fountain Healthcare Partners (“Fountain”) announced on 5/23/19 the initial closing of its third fund, Fountain Healthcare Partners Fund III, L.P. (“Fund III”) with €118 million of committed... read more